Atara Biotherapeutics (ATRA) Net Cash Flow Growth (1y) (2014 - 2026)
Atara Biotherapeutics (ATRA) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,045.25% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -104.22% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 149.49% |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | -276.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -276.23% |
| Mar 31, 2026 | 98.91% |
| Dec 31, 2025 | 112.79% |
| Sep 30, 2025 | -173.72% |
| Jun 30, 2025 | 177.29% |
| Mar 31, 2025 | -221.01% |
| Dec 31, 2024 | 45.00% |
| Sep 30, 2024 | -19.87% |
| Jun 30, 2024 | -32.71% |
| Mar 31, 2024 | 120.92% |
| Dec 31, 2023 | -246.27% |
| Sep 30, 2023 | 438.95% |
| Jun 30, 2023 | 90.82% |
| Mar 31, 2023 | -890.39% |
| Dec 31, 2022 | 473.73% |
| Sep 30, 2022 | 47.65% |
| Jun 30, 2022 | -13.73% |
| Mar 31, 2022 | 90.95% |
| Dec 31, 2021 | -105.17% |
| Sep 30, 2021 | 10.46% |